Friday, March 24, 2017 11:12:04 AM
Goldenisla,
Your question on Warrants is a good one to understand. As stated many here own Warrants that have a .75 cost to convert. So they are in the money at a SP above .75. It takes 7-10 days to covert a Warrant to a non restricted share that can be sold. The .75 goes into the company's coffers and that is a good thing. The real pressure on the SP above .75 is not actually the Warrant but the shares that were purchased at .75 to obtain the Warrant rights. Those are the shares that are being unloaded in favor of keeping the risk free Warrants. So with a slow run up on SP in the mid 70's and 80's we will see some of that selling pressure. Major catalysts that blow by those levels into the $1.50 range may change that strategy as to perceived risk and further upside and many that were selling MAY adjust their strategy. Nothing is for sure but those are some of the scenarios.
Your question on Warrants is a good one to understand. As stated many here own Warrants that have a .75 cost to convert. So they are in the money at a SP above .75. It takes 7-10 days to covert a Warrant to a non restricted share that can be sold. The .75 goes into the company's coffers and that is a good thing. The real pressure on the SP above .75 is not actually the Warrant but the shares that were purchased at .75 to obtain the Warrant rights. Those are the shares that are being unloaded in favor of keeping the risk free Warrants. So with a slow run up on SP in the mid 70's and 80's we will see some of that selling pressure. Major catalysts that blow by those levels into the $1.50 range may change that strategy as to perceived risk and further upside and many that were selling MAY adjust their strategy. Nothing is for sure but those are some of the scenarios.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:40:20 PM
- CytoDyn Announces Resolution of Class Action Lawsuit • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
